Blue Cross | Blue Shield | Blue Care Network of Michigan The Record

Stethoscope with RX papers

Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print this article

November 2019

Blue Cross and BCN to cover select hyaluronic acid products, starting Jan. 1

Effective Jan. 1, 2020, Blue Cross Blue Shield of Michigan and Blue Care Network will consider the following hyaluronic acid products to be either covered or preferred under the medical benefit:

  • Durolane®
  • Euflexxa®
  • Gelsyn-3
  • Supartz FX

Starting Jan. 1, the following will be considered either noncovered or nonpreferred hyaluronic acid products:

  • Gel-one®
  • GenVisc 850®
  • Hyalgan®
  • Hymovis®
  • Monovisc®
  • Orthovisc®
  • Synvisc®
  • Synvisc-One®
  • TriVisc®
  • Visco-3
  • Synojoynt
  • Triluron

This change will apply to Blue Cross’ PPO, Medicare Plus BlueSM PPO, BCN HMOSM and BCN AdvantageSM members. This change won’t apply to self-funded General Motors, Fiat Chrysler Automobiles, Ford Motor Company and UAW Retiree Medical Benefit Trust commercial groups.

Blue Cross’ PPO and BCN HMO commercial members

  • Members who began receiving noncovered hyaluronic acid products before Jan. 1, 2020, can continue their treatment courses to completion. For future treatment courses that begin on or after Jan. 1, 2020, we encourage providers to talk to their patients about using a covered hyaluronic acid product.
  • For treatment courses that begin on or after Jan. 1, 2020, we’ll require members to use a covered hyaluronic acid product. These products don’t need prior authorization.
  • We’ll deny claims for noncovered hyaluronic acid drugs.
  • We’ll notify affected members of these changes and encourage them to discuss treatment options with you.

Medicare Plus Blue and BCN Advantage members

  • Members who began receiving nonpreferred hyaluronic acid products before Jan. 1, 2020, can continue their treatment courses to completion. For future treatment courses that begin on or after Jan. 1, 2020, we encourage providers to talk to their patients about using a preferred hyaluronic acid product.
  • For treatments on or after Jan. 1, 2020, we’ll require members to use preferred hyaluronic acid products. These products won’t need prior authorization. If you select a nonpreferred hyaluronic acid product for a member, you’ll have to obtain prior authorization.

Additional information

The U.S. Food and Drug Administration has approved 16 hyaluronic acid products. To date, no study has shown that one hyaluronic acid product is superior to others.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2018 American Medical Association. All rights reserved.